source
- Avalo scores Phase 2 success in comeback bid, raises $375MAvalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experim…Endpoints · 2mo ago↗ source
- GSK goes to China for $1B siRNA deal in Arrowhead's obesity laneGSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzho…Endpoints · 2mo ago↗ source
- CellCentric raises $220M to get multiple myeloma pill to marketCellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…